Small-cell neuroendocrine tumors (SCNTs) represent an aggressive group of difficult-to-treat tumors with shared characteristics that pose significant challenges in patient care.
The Robert A. Winn Diversity In Clinical Trials Award Program Increasing diversity in clinical trials to reduce health disparities and improve health outcomes in all…
AbstractArtificial intelligence (AI) in oncology is advancing beyond algorithm development to integration into clinical practice. This review describes the current state of the field, with…
NYU Langone’s New York Female Asian Nonsmoker Screening Study (FANSS) explores early detection of lung cancer in this high-risk population.
Summary:. The NCI director presents her vision of the National Cancer Plan as an integrated framework that can help drive innovation in cancer research to…
Following disappointing Phase III results in less aggressive non-small cell lung cancer, AstraZeneca on Friday announced that Imfinzi improved progression-free and overall survival in patients…
2024 AACR Runners for Research 5K Run/WalkEvent landing page for 2024 AACR Runners for Research 5K Run/Walk
WASHINGTON, D.C. (March 18, 2024) —Today, National Minority Quality Forum (NMQF) announced its 40 Under 40 Leaders in Minority Health for 2024 that will receive…
This project explores the diverse effects of autoantibodies on cancer immunotherapy outcomes, seeking to understand why patients respond so differently to treatment. Using a new…
This project explores the diverse effects of autoantibodies on cancer immunotherapy outcomes, seeking to understand why patients respond so differently to treatment. Using a new…
This year, nearly 250,000 Americans will be diagnosed with lung cancer, the leading cause of cancer death in the United States. During National…
